ID

45636

Beschreibung

Principal Investigator: Christopher I Amos, PhD, Geisel School of Medicine at Dartmouth, Hanover, NH, USA MeSH: Breast Neoplasms,Ovarian Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001321 The data come from 40 studies participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). CIMBA recruits individuals with pathogenic mutations in BRCA1 or BRCA2. The majority of carriers were recruited through cancer genetics clinics offering genetic testing, and were enrolled into national or regional studies. The remainder were identified by population-based sampling of cases, or community recruitment. Eligibility to participate is restricted to carriers of pathogenic BRCA1/2 mutations who were 18 years or older at recruitment. Information collected included amongst other variables: age at recruitment; ages at breast and ovarian cancer diagnosis; and estrogen receptor (ER) status. Samples were genotyped using the Illumina OncoArray beadchip 500K SNP custom array. Details of the genotyping process and sample selection are included in Phelan et al, Identification of twelve new susceptibility loci for different histotypes of epithelial ovarian cancer, Nat Genet. 2017 May;49(5):680-691 (PMID:28346442), and Milne et al, Identification of ten variants associated with risk of estrogen receptor negative breast cancer, Nat Genet (in press).

Link

dbGaP study = phs001321

Stichworte

  1. 09.03.23 09.03.23 - Simon Heim
Rechteinhaber

Christopher I Amos, PhD, Geisel School of Medicine at Dartmouth, Hanover, NH, USA

Hochgeladen am

9. März 2023

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :


Keine Kommentare

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

dbGaP phs001321 Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

Eligibility Criteria

Inclusion and exclusion criteria
Beschreibung

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
Samples were genotyped using the Illumina OncoArray Beadchip 500K SNP custom array. Samples with call rates <95% and samples with extreme heterozygosity (>4.9 standard deviations from the mean for the reported ethnicity) were excluded. Samples were also excluded if they were of non-European ancestry using multi-dimensional scaling analysis. The sample quality control process is described in detail in Milne et al, Identification of ten variants associated with risk of estrogen receptor negative breast cancer, Nat Genet (in press). Related individuals are retained in the sample. The OncoArray SNP quality control process is described in detail in Amos et al, The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers, Cancer Epidemiol Biomarkers Prev. 2017. PubMed_link
Beschreibung

Samples were genotyped using the Illumina OncoArray Beadchip 500K SNP custom array. Samples with call rates <95% and samples with extreme heterozygosity (>4.9 standard deviations from the mean for the reported ethnicity) were excluded. Samples were also excluded if they were of non-European ancestry using multi-dimensional scaling analysis. The sample quality control process is described in detail in Milne et al, Identification of ten variants associated with risk of estrogen receptor negative breast cancer, Nat Genet (in press). Related individuals are retained in the sample. The OncoArray SNP quality control process is described in detail in Amos et al, The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers, Cancer Epidemiol Biomarkers Prev. 2017. PubMed_link

Datentyp

boolean

Alias
UMLS CUI [1,1]
C5441552
UMLS CUI [1,2]
C1136352
UMLS CUI [1,3]
C0006826
UMLS CUI [1,4]
C1709626
UMLS CUI [1,5]
C0041366
UMLS CUI [1,6]
C0370003
UMLS CUI [1,7]
C1285573
UMLS CUI [1,8]
C4687476
UMLS CUI [1,9]
C0752046
UMLS CUI [1,10]
C2828389
UMLS CUI [1,11]
C1518422
UMLS CUI [1,12]
C1257905
UMLS CUI [1,13]
C0681930
UMLS CUI [1,14]
C0034378
UMLS CUI [1,15]
C0035647
UMLS CUI [1,16]
C4733092
UMLS CUI [1,17]
C1880171

Ähnliche Modelle

Eligibility Criteria

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
Samples were genotyped using the Illumina OncoArray Beadchip 500K SNP custom array. Samples with call rates <95% and samples with extreme heterozygosity (>4.9 standard deviations from the mean for the reported ethnicity) were excluded. Samples were also excluded if they were of non-European ancestry using multi-dimensional scaling analysis. The sample quality control process is described in detail in Milne et al, Identification of ten variants associated with risk of estrogen receptor negative breast cancer, Nat Genet (in press). Related individuals are retained in the sample. The OncoArray SNP quality control process is described in detail in Amos et al, The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers, Cancer Epidemiol Biomarkers Prev. 2017. PubMed_link
Item
Samples were genotyped using the Illumina OncoArray Beadchip 500K SNP custom array. Samples with call rates <95% and samples with extreme heterozygosity (>4.9 standard deviations from the mean for the reported ethnicity) were excluded. Samples were also excluded if they were of non-European ancestry using multi-dimensional scaling analysis. The sample quality control process is described in detail in Milne et al, Identification of ten variants associated with risk of estrogen receptor negative breast cancer, Nat Genet (in press). Related individuals are retained in the sample. The OncoArray SNP quality control process is described in detail in Amos et al, The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers, Cancer Epidemiol Biomarkers Prev. 2017. PubMed_link
boolean
C5441552 (UMLS CUI [1,1])
C1136352 (UMLS CUI [1,2])
C0006826 (UMLS CUI [1,3])
C1709626 (UMLS CUI [1,4])
C0041366 (UMLS CUI [1,5])
C0370003 (UMLS CUI [1,6])
C1285573 (UMLS CUI [1,7])
C4687476 (UMLS CUI [1,8])
C0752046 (UMLS CUI [1,9])
C2828389 (UMLS CUI [1,10])
C1518422 (UMLS CUI [1,11])
C1257905 (UMLS CUI [1,12])
C0681930 (UMLS CUI [1,13])
C0034378 (UMLS CUI [1,14])
C0035647 (UMLS CUI [1,15])
C4733092 (UMLS CUI [1,16])
C1880171 (UMLS CUI [1,17])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video